Abstract
α1-Adrenoceptor antagonists, called α1-blockers, are the first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Nonselective α1-blockers like prazosin were mainly used in the past, but prostate-specific α1-blockers such as tamsulosin or naftopidil are now the mainstream agents for the management of BPH, based on the function of α1-adrenoceptor subtypes. Recent studies on voiding dysfunction have clarified the association between BPH and overactive bladder (OAB), underlining the use of OAB treatment in the management of BPH, inducing the simultaneous administration of antimuscarinic agents. Every aspect of diversified BPH symptom can be controlled individually in a short period.
